Evidence map›Paper›PMID 42694471›Full record

ArticleJCEM case reports2026

Dabrafenib and trametinib-induced hyperglycemia with decreased insulin secretion in a patient with lung adenocarcinoma.

Kohei Nagano, Masaki Suzuki, Saki Morikawa, Rikiya Watanabe, Takeshi Ohara, Kenta Hara

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in JCEM case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kohei NaganoDepartment of Diabetes and Endocrine Disease, Kita-Harima Medical Center, Ono 675-1392, Japan.ORCID https://orcid.org/0009-0001-0555-1456
Masaki SuzukiDepartment of Diabetes and Endocrine Disease, Kita-Harima Medical Center, Ono 675-1392, Japan.ORCID https://orcid.org/0000-0002-0677-7828
Saki MorikawaDepartment of Diabetes and Endocrine Disease, Kita-Harima Medical Center, Ono 675-1392, Japan.
Rikiya WatanabeDepartment of General Internal Medicine, Kita-Harima Medical Center, Ono 675-1392, Japan.
Takeshi OharaDepartment of Diabetes and Endocrine Disease, Kita-Harima Medical Center, Ono 675-1392, Japan.
Kenta HaraDepartment of Diabetes and Endocrine Disease, Kita-Harima Medical Center, Ono 675-1392, Japan.ORCID https://orcid.org/0000-0002-1987-9356

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hyperglycemia is an adverse effect of targeted cancer therapies; however, the mechanisms underlying B-Raf proto-oncogene, serine/threonine kinase (BRAF)/mitogen-activated protein kinase kinase (MEK) inhibitor-associated hyperglycemia remain unclear. We describe an 80-year-old man who developed severe hyperglycemia during combination therapy with dabrafenib and trametinib for

Indexed as

BRAFdiabetes mellituslung adenocarcinomaMEKβ-cell

Identifiers

PMID42694471
PMCPMC13538961

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.